Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Centessa Pharmaceuticals ( (CNTA) ) just unveiled an update.
On June 16, 2025, Centessa Pharmaceuticals announced that the FDA has cleared their Investigational New Drug application for ORX142, allowing the initiation of a Phase 1 clinical study in healthy volunteers. ORX142, a novel OX2R agonist, is being developed for neurological and neurodegenerative disorders, marking a significant milestone in Centessa’s clinical development. The study will assess the safety and pharmacokinetics of ORX142, with clinical data expected later this year, potentially impacting the company’s positioning in addressing unmet needs in these disorders.
The most recent analyst rating on (CNTA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering transformational medicines. The company is pioneering therapies within its orexin receptor 2 (OX2R) agonist program to address symptoms such as excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue across neurological, neurodegenerative, and neuropsychiatric disorders. Centessa also has an early-stage immuno-oncology program utilizing its LockBody® technology platform.
Average Trading Volume: 948,713
Technical Sentiment Signal: Hold
Current Market Cap: $1.68B
See more insights into CNTA stock on TipRanks’ Stock Analysis page.